Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ozlem Bilen

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
European Radiology|August 20, 2025
Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging for non-sustained ventricular tachycardia and sudden cardiac death in hypertrophic cardiomyopathy: a meta-analysisAhmed Kamal Siddiqi, Muhammad Talha Maniya, Ozlem Bilen, et al.
Pediatric Blood & Cancer|November 7, 2012
Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurementEmily B Franzblau, Rowena C Punzalan, Kenneth D Friedman, et al.
Clinical Cardiology|January 25, 2024
A systematic review of present and future pharmaco-structural therapies for hypertrophic cardiomyopathyMariem A Sawan, Sindhu Prabakaran, Melroy D'Souza, et al.
Circulation. Cardiovascular Interventions|January 26, 2026
Fatal Steam Pop Complicating Investigational SESAME Transcatheter Myotomy Using Off-the-Shelf EquipmentRobert J Lederman, Adam B Greenbaum, Rim N Halaby, et al.
Circulation. Genomic and Precision Medicine|November 10, 2025
Mavacamten Monotherapy in Real-World Patients with Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCMOzlem Bilen, Arnon Shmuel Adler, Rachel Bastiaenen, et al.
JACC. Heart Failure|April 26, 2025
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic CardiomyopathyAhmad Masri, Martin S Maron, Theodore P Abraham, et al.
JACC. Heart Failure|February 5, 2025
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline CharacteristicsPablo Garcia-Pavia, Ozlem Bilen, Melissa Burroughs, et al.
The New England Journal of Medicine|September 1, 2025
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic CardiomyopathyPablo Garcia-Pavia, Martin S Maron, Ahmad Masri, et al.
Journal of the American College of Cardiology|December 5, 2025
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM TrialAndrew Wang, Pablo Garcia-Pavia, Ahmad Masri, et al.
Journal of the American College of Cardiology|September 11, 2025
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCMSheila M Hegde, Xiaowen Wang, Pablo Garcia-Pavia, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
European Radiology|August 20, 2025
Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging for non-sustained ventricular tachycardia and sudden cardiac death in hypertrophic cardiomyopathy: a meta-analysisAhmed Kamal Siddiqi, Muhammad Talha Maniya, Ozlem Bilen, et al.
Pediatric Blood & Cancer|November 7, 2012
Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurementEmily B Franzblau, Rowena C Punzalan, Kenneth D Friedman, et al.
Clinical Cardiology|January 25, 2024
A systematic review of present and future pharmaco-structural therapies for hypertrophic cardiomyopathyMariem A Sawan, Sindhu Prabakaran, Melroy D'Souza, et al.
Circulation. Cardiovascular Interventions|January 26, 2026
Fatal Steam Pop Complicating Investigational SESAME Transcatheter Myotomy Using Off-the-Shelf EquipmentRobert J Lederman, Adam B Greenbaum, Rim N Halaby, et al.
Circulation. Genomic and Precision Medicine|November 10, 2025
Mavacamten Monotherapy in Real-World Patients with Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCMOzlem Bilen, Arnon Shmuel Adler, Rachel Bastiaenen, et al.
JACC. Heart Failure|April 26, 2025
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic CardiomyopathyAhmad Masri, Martin S Maron, Theodore P Abraham, et al.
JACC. Heart Failure|February 5, 2025
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline CharacteristicsPablo Garcia-Pavia, Ozlem Bilen, Melissa Burroughs, et al.
The New England Journal of Medicine|September 1, 2025
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic CardiomyopathyPablo Garcia-Pavia, Martin S Maron, Ahmad Masri, et al.
Journal of the American College of Cardiology|December 5, 2025
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM TrialAndrew Wang, Pablo Garcia-Pavia, Ahmad Masri, et al.
Journal of the American College of Cardiology|September 11, 2025
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCMSheila M Hegde, Xiaowen Wang, Pablo Garcia-Pavia, et al.
Pageof 3